Medable has unveiled its new technology designed to improve recruitment, retention and diversity in clinical trials of cancer therapies.
The latest offering by the trial software firm features prebuilt and validated decentralized clinical trial applications such as Total Consent and Televisit, an extensive electronic clinical outcome assessment oncology library, as well as protocol design consulting and a single point of entry for patients, sites and sponsors, the company said in an Oct. 26 press release.
The technology is designed to help overcome traditional obstacles in oncology trials such as identifying the most appropriate patients and ensuring a diverse population of participants. About two-thirds of oncology trials close early due to low enrollment numbers, with less than 5% of adult cancer patients signing up for research trials despite nearly 2 million people being diagnosed with cancer every year, the company pointed out.
“The reinvigorated Cancer Moonshot initiative coupled with the FDA’s emphasis on diversity in clinical research is driving an urgent need to improve access to cancer trials,” Musaddiq Khan, Medable vice president of therapeutic area solutions, said in the release. “Our DCT offering is designed around the core needs of oncology trials while enabling optionality to improve access and the patient experience.”
The company said it has already screened over 22,000 cancer patients through its current platform at 3,300 sites and 60 countries.
In September, Medable inked a four-year deal with GSK to use its platform for decentralized clinical trials and to recruit more diverse trial populations across the drugmaker’s portfolio of products.